会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • Protein farnesyl transferase inhibitors
    • 蛋白法呢基转移酶抑制剂
    • US5523430A
    • 1996-06-04
    • US247743
    • 1994-05-23
    • Dinesh V. PatelScott A. BillerEric M. Gordon
    • Dinesh V. PatelScott A. BillerEric M. Gordon
    • C07C57/13C07C233/49C07F9/38C07C233/00
    • C07F9/3808C07C233/49C07C57/13C07F9/3826
    • Inhibition of farnesyl transferase, which is an enzyme involved in ras oncogene expression, and inhibition of cholesterol biosynthesis, are effected by compounds of the formula ##STR1## their enantiomers, diastereomers, and pharmaceutically acceptable salts, prodrugs, and solvates, wherein:X is --ONR.sup.1 C(O)--, --N(OR.sup.1)C(O)--, --NR.sup.1 C(O)--, --C(O)NR.sup.1 --, --NR.sup.1 S(O.sub.2)--, --C(O)O--, --OC(O)--, --O--, --NR.sup.1 -- or --(S)q;Y and Z are each independently --CO.sub.2 R.sup.2, --SO.sub.3 R.sup.2 or --P(O)(OR.sup.2)(OR.sup.3);R is alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkenylene or aryl;R.sup.1, R.sup.2 and R.sup.3 are each independently hydrogen, alkyl, aryl or aralkyl;m and n are each independently 0 or an integer from 1 to 5;p is 0 or 1; andq is an integer from 1 to 2.
    • 抑制参与ras癌基因表达的酶的法呢基转移酶和胆固醇生物合成的抑制由下式的化合物影响:它们的对映异构体,非对映异构体和药学上可接受的盐,前药和溶剂合物,其中:X是 (O) - , - N(OR 1)C(O) - , - NR 1 C(O) - , - C(O)NR 1 - , - NR 1 S(O 2) - , - (O) - , - O - , - NR 1 - 或 - (S)q; Y和Z各自独立地为-CO 2 R 2,-SO 3 R 2或-P(O)(OR 2)(OR 3); R是烷基,取代的烷基,烯基,取代的烯基,亚烯基或芳基; R1,R2和R3各自独立地为氢,烷基,芳基或芳烷基; m和n各自独立地为0或1至5的整数; p为0或1; q为1〜2的整数。
    • 2. 发明授权
    • Inhibitors of farnesyl protein transferase
    • 法呢基蛋白转移酶抑制剂
    • US5510510A
    • 1996-04-23
    • US267080
    • 1994-06-28
    • Dinesh V. PatelScott A. Biller
    • Dinesh V. PatelScott A. Biller
    • C07C233/05C07C259/06C07F9/38C07F9/40C07C69/02
    • C07F9/3808C07C233/05C07C259/06C07F9/4075
    • Inhibition of farnesyl transferase, which is an enzyme involved in ras oncogene expression, and inhibition of cholesterol biosynthesis, are effected by compounds of the formula ##STR1## their enantiomers, diastereomers, and pharmaceutically acceptable salts, prodrugs, and solvates, wherein:x is --ONR.sup.1 C(O)--, --N(OR.sup.1)C(O)--, --NR.sup.1 C(O)--, --C(O)NR.sup.1 --, --NR.sup.1 S(O.sub.2)--, --C(O)O--, --OC(O)--, --C(O)--, --O--, --NR.sup.1 -- or --(S).sub.q --;Y is --CO.sub.2 R.sup.2, --SO.sub.3 R.sup.2 or --P(O) (OR.sup.2) (R.sup.3);R is alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkenylene or aryl;R.sup.3 is --(O).sub.t R.sup.4 ;R.sup.1, R.sup.2 and R.sup.4 are each independently hydrogen, alkyl, aryl or aralkyl;m and n are each independently 0 or an integer from 1 to 5;p and t are each independently 0 or 1; andq is an integer from 1 to 2.
    • 抑制作为参与ras癌基因表达的酶的法呢基转移酶和胆固醇生物合成的抑制由下式的化合物影响其对映异构体,非对映异构体和药学上可接受的盐,前药和溶剂化物,其中:x是 (O) - , - N(OR 1)C(O) - , - NR 1 C(O) - , - C(O)NR 1 - , - NR 1 S(O 2) - , - (O) - , - C(O) - , - O - , - NR1-或 - (S)q-; Y是-CO 2 R 2,-SO 3 R 2或-P(O)(OR 2)(R 3); R是烷基,取代的烷基,烯基,取代的烯基,亚烯基或芳基; R3为 - (O)tR4; R1,R2和R4各自独立地为氢,烷基,芳基或芳烷基; m和n各自独立地为0或1至5的整数; p和t各自独立地为0或1; q为1〜2的整数。